Navigation Links
New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma

- Positive data on subcutaneous administration show potential for new option to improve convenience for patients -

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced the presentation of positive data for VELCADE, the market-leading therapy for patients with multiple myeloma (MM) who have received at least one prior therapy. These data include results from a Phase II trial for subcutaneous (SC) administration of VELCADE, a new option under evaluation. Results were also presented from the international Phase III trial of VELCADE + DOXIL, which served as the basis for the recent U.S. approval of the combination and showed significant improvement in time to disease progression compared to VELCADE alone, the current standard of care. The VELCADE + DOXIL abstract was selected by the Best of the American Society of Clinical Oncology (ASCO) Program Committee as one of the premier abstracts at the 43rd Annual Meeting in Chicago.

"We and our partner Johnson & Johnson Pharmaceutical Research and Development L.L.C. continue to develop new clinical data that reinforce the role of VELCADE as the U.S. market-leading therapy in previously treated multiple myeloma," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "These data demonstrate that VELCADE in combination with another active agent can further strengthen the unparalleled impact of VELCADE. We are aggressively pursuing development of a subcutaneous delivery form to broaden alternatives for patients who prefer to receive VELCADE treatment at home."

Prospective Comparison of Subcutaneous to Intravenous Administration of Bortezomib in Patients with Multiple Myeloma: Pharmacokinetics, Efficacy and Toxicity (Abstract #8046)

This randomized trial evaluated the pharmacokinetics/pharmacodynamics (PK/PD), toxicity and response rate of VELCADE in patients treated with either an SC or intravenous
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
5. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
10. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
11. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
Post Your Comments:
(Date:5/22/2015)...  BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading ... storage and cryopreservation freeze media and ... or the "Company"), announced that the Company is scheduled to ... The Company is scheduled to present at the Conference at ... Grand Hyatt Hotel in New York City ...
(Date:5/22/2015)... , May 22, 2015 The ... the $13 billion global cardiac rhythm management device ... Kalorama found that Medtronic, St. Jude Medical, Boston ... 80% of this market segment. The healthcare market ... Markets , uses 2015 as a base year, ...
(Date:5/22/2015)... , May 22, 2015  The U.S. Food ... (filgrastim-sndz) -- the first biosimilar product approved in ... points toward growth in the contract manufacturing organization ... CMO industry is geared to the production of ... major biopharmaceutical products. The healthcare market research publisher,s ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... THE WOODLANDS, Texas, Sept. 30, 2011 David, a ... grandfather, felt too young to be diagnosed with prostate ... symptoms." David, under the advisement of his oncologist, decided ... first in a new therapeutic class known as autologous ...
... 30, 2011 The CyberKnife Coalition announced ... CyberKnife Robotic Radiosurgery System® have now been enrolled in ... prostate cancer patients treated with stereotactic body ... (RPCR), tracks clinical and functional outcomes of men with ...
Cached Medicine Technology:The US Oncology Network Affiliated Physicians at Forefront of Cutting-Edge Prostate Cancer Treatment 2The US Oncology Network Affiliated Physicians at Forefront of Cutting-Edge Prostate Cancer Treatment 3The US Oncology Network Affiliated Physicians at Forefront of Cutting-Edge Prostate Cancer Treatment 4First Prostate Cancer Registry for Robotic Radiosurgery Patients Enrolls More than 500 Men 2
(Date:5/22/2015)... The world is at a "hinge ... to create new opportunities for leadership in health ... WesternU's 34th annual Commencement Exercises said Wednesday, May ... former San Francisco mayor and likely 2018 gubernatorial ... ceremony for WesternU's colleges of Allied Health Professions ...
(Date:5/22/2015)... The American College of Traditional Chinese Medicine ... will hold a webinar on the updates of the ... Classical Chinese Medicine. , Webinar – First Professional Doctorate ... Dean of Clinical Education, will lead this webinar in ... program. ACTCM is currently developing this degree program based ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board ... system’s Chief Financial Officer (CFO), will be leaving the ... the company CFO since 2011. , The Board of ... health system as CFO. Wesley will oversee the health ... Board of Trustees conducts a formal search for a ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health Limited ... brand Nature’s Way, Marc St-Onge has affirmed his commitment ... is an integral part of the agreement with Nature’s ... further develop Ascenta Skin into a leading player in ... breakthrough, anti-aging skincare supplement featuring 6 active ingredients including ...
(Date:5/22/2015)... UK (PRWEB) May 22, 2015 ... leading treatment option for chronic obstructive pulmonary disorder ... GlaxoSmithKline plc and AstraZeneca plc as well as ... market share and position. But will market payers, ... the already well-entrenched products to completely new ones? ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
... Pa., Oct. 31 After already launching three,well-received ... the newest additions to its healthy snacks available ... to fit their own style,and schedule. Continuing their ... added two new options with a variety of ...
... (+44% y/y) - 2008 EPS Guidance Increased ... - ... HMS Holdings Corp. (Nasdaq:,HMSY) today announced its financial results for the third ... September 30, 2008 revenue increased 30% to $49.0,million, compared with $37.7 million ...
... 2.0 tools by suppliers in the senior care marketplace? Are print advertising ... are answered in our latest “Trends in Senior Care Marketing" report. ... ... use of blogs, podcasts and other Web 2.0 tools by suppliers in ...
... coma, 6 year chronic sciatica back pain, 15- and 25-year ... these conditions were overcome using advanced magnetic therapy techniques developed ... ... (PRWEB) October 31, 2008 -- Regenerating nerves, waking people from ...
... should not give up and start over after they,ve been denied disability ... ... Belleville, Ill. (Vocus) October 31, 2008 -- Getting a denial letter after ... leads some people to call it quits, according to Allsup , ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) management will present at ... at 8:00 AM at,the Waldorf-Astoria Hotel., The conference will also ... The webcast can be accessed at, http://www.celltherapeutics.com ., ... 19th Annual Healthcare Conference ...
Cached Medicine News:Health News:Lifestyle Foods Introduces Two New Healthy Snack Options 2Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 2Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 3Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 4Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 5Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 6Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 7Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 8Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 9Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 10Health News:Complimentary White Paper: Where Senior Care Suppliers Spent Marketing and PR Dollars in 2007 and 2008 2Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 2Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 3Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 4Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 5Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 2Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 3Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 4Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 5Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 6
... Screening (HTS), Analyst HT smoothes the ... sharing all the detection modalities and ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ... into robotic environments, including those from ...
... all the right features for assay ... simple instrument control. Reduces the inevitable ... into HTS. Specifically developed to meet ... Analyst AD delivers unparalleled detection performance ...
... FLUOstar is a flexible multifunction plate reader ... one instrument: fluorescence intensity, time-resolved fluorescence, high-perfomance ... be equipped with injectors that deliver reagent ... fast kinetic cell assays can be performed ...
This new dedicated VICTOR2 model is for fluorescence and luminescence measurements....
Medicine Products: